Key points are not available for this paper at this time.
Background Inclisiran is a small interfering RNA that safely and effectively lowers low-density lipoprotein cholesterol (LDL-C) with twice-yearly dosing (after the initial and 3-month doses). However, data on real-world inclisiran use are limited. Objective This descriptive, non-interventional, retrospective chart review aimed to assess dosing schedule adherence, patient profiles, and LDL-C change in participants prescribed inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in routine clinical practice in Austria. Methods Participants with ASCVD, ASCVD risk equivalent, or familial hypercholesterolemia, LDL-C ≥70 mg/dL <6 months before the first inclisiran dose who received ≥1 inclisiran dose between 1-Feb-2021 and 30-Jun-2022 were included. Results Of participants who initiated inclisiran (N=95), 96.8% and 89.5% received the second and third doses, respectively, with 95.5% receiving the second dose <5 months of the first dose and 73.4% receiving the third dose 6–9 months after the second dose. At baseline, median LDL-C was high (122.0 mg/dL) despite 77.9% of participants receiving lipid-lowering therapy (LLT); concomitant LLT use was reduced to 55.8% after initiating inclisiran. Median LDL-C reduction after first and second doses was 44.7% and 40.8%, respectively. In a sub-cohort with concomitant statin use, median LDL-C reduction from baseline was 55.7% and 56.0% after the first and second dose, respectively, with 87.9% achieving LDL-C <55 mg/dL after second or third dose. Absolute LDL-C reduction was consistent irrespective of concomitant statin use. Conclusions In a real-world setting in Austria, inclisiran demonstrated favorable early therapeutic impact, including high adherence to the recommended dosing schedule and sustained LDL-C reductions.
Pätzold et al. (Wed,) studied this question.